Accuray Appoints New CEO

Euan S. Thomson, former president, CEO, and board director of radiation oncology company Accuray Inc., resigned from his position on Oct. 12. Assuming the role is Joshua H. Levine, who also is acting as a consultant for the company.

Thomson joined Accuray in March 2002 as CEO, was appointed president in September 2002 and served on the board of directors. During his tenure, Thomson expanded the radiosurgery market with the company’s flagship product, the CyberKnife system (a robotic radiosurgery system). He took the company public in February 2007 and orchestrated the 2011 acquisition of TomoTherapy, which added the TomoTherapy system (a 3-D conformal radiation therapy and intensity-modulated radiation therapy system) to the firm’s product portfolio, thereby expanding its presence in the radiation therapy market.

Thomson thanked the company and its customers in a statement for “their support and encouragement over the last 10 years as [they] changed the way people think about treating cancer patients.”

“Euan was instrumental in growing Accuray’s installed base from approximately five to more than 642 systems and growing the company from approximately 75 to over 1,100 employees,” said Louis J. Lavigne Jr., board chairman. “With the acquisition of TomoTherapy we are now ready for the next stage of growth. Capitalizing on the progress made by Euan, the board attracted Joshua Levine, who the board believes is an experienced, commercially oriented CEO with diverse global healthcare experience necessary to lead the company to the next level of success.”

Levine was CEO of Mentor Corporation. He led the company through a strategic transformation and was instrumental in securing its sale to a franchise of Johnson & Johnson in January 2009; most recently Levine was CEO of Immucor Corporation until its October 2011 acquisition by TPG Capital. Levine holds a Bachelor of Arts degree in communications from the University of Arizona and has completed executive management programs at Stanford University, Graduate School of Business in Stanford, Calif., and the University of Pennsylvania, Wharton School in Philadelphia, Pa.

“Accuray has a history of technical innovations in the radiation oncology field that have helped support the personalized clinical needs of cancer patients and the radiation oncologists who treat them,” said Levine. “I look forward to working with all of Accuray’s employees to help build growth producing value for all of the company’s constituents—shareholders, customers, and employees alike.”

Accuray Inc., based in Sunnyvale, Calif., develops, manufactures and sells technology designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy.

Photo of Levine courtesy of Accuray Inc.